The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The t(4;14) translocation and FGFR3 overexpression in multiple myeloma: prognostic implications and current clinical strategies
Authors
Keywords
-
Journal
Blood Cancer Journal
Volume 2, Issue 9, Pages e89-e89
Publisher
Springer Nature
Online
2012-09-07
DOI
10.1038/bcj.2012.37
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Progression from MGUS to Smoldering Myeloma and Eventually to Multiple Myeloma Involves a Clonal Expansion of Genetically Abnormal Plasma Cells
- (2011) L. Lopez-Corral et al. CLINICAL CANCER RESEARCH
- The Histone Methyltransferase and Putative Oncoprotein MMSET Is Overexpressed in a Large Variety of Human Tumors
- (2011) H. R. Hudlebusch et al. CLINICAL CANCER RESEARCH
- Clinical and biological features of t(4;14) multiple myeloma: a prospective study
- (2011) Lionel Karlin et al. LEUKEMIA & LYMPHOMA
- MMSET regulates histone H4K20 methylation and 53BP1 accumulation at DNA damage sites
- (2011) Huadong Pei et al. NATURE
- The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
- (2010) E. Martinez-Garcia et al. BLOOD
- Combining information regarding chromosomal aberrations t(4;14) and del(17p13) with the International Staging System classification allows stratification of myeloma patients undergoing autologous stem cell transplantation
- (2010) K. Neben et al. HAEMATOLOGICA
- Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)
- (2010) Hervé Avet-Loiseau et al. JOURNAL OF CLINICAL ONCOLOGY
- Clinical impact of chromosomal aberrations in multiple myeloma
- (2010) H. Nahi et al. JOURNAL OF INTERNAL MEDICINE
- Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
- (2010) H Avet-Loiseau et al. LEUKEMIA
- Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13
- (2009) D. Reece et al. BLOOD
- FGFR3 amplification in the absence of IGH@–FGFR3 fusion t(4;14) in myeloma
- (2009) Fabiola Quintero-Rivera et al. CANCER GENETICS AND CYTOGENETICS
- Bortezomib, Dexamethasone, and Fibroblast Growth Factor Receptor 3-Specific Tyrosine Kinase Inhibitor in t(4;14) Myeloma
- (2009) G. Bisping et al. CLINICAL CANCER RESEARCH
- Clinical and Immunohistochemical Features Associated with a Response to Bortezomib in Patients with Multiple Myeloma
- (2009) M. A. Dawson et al. CLINICAL CANCER RESEARCH
- FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14)
- (2009) Thea K. Våtsveen et al. EUROPEAN JOURNAL OF HAEMATOLOGY
- Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice
- (2009) Jing Qing et al. JOURNAL OF CLINICAL INVESTIGATION
- International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
- (2009) R Fonseca et al. LEUKEMIA
- Management of Newly Diagnosed Symptomatic Multiple Myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) Consensus Guidelines
- (2009) Shaji K. Kumar et al. MAYO CLINIC PROCEEDINGS
- Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2
- (2008) Mauricio Pineda-Roman et al. BRITISH JOURNAL OF HAEMATOLOGY
- A Phase I Pharmacokinetic and Pharmacodynamic Study of TKI258, an Oral, Multitargeted Receptor Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors
- (2008) D. Sarker et al. CLINICAL CANCER RESEARCH
- Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome
- (2008) Olivier Decaux et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of genetic abnormalities on survival after allogeneic hematopoietic stem cell transplantation in multiple myeloma
- (2008) G Schilling et al. LEUKEMIA
- Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma
- (2008) Jesús F. San Miguel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Drug-sensitive FGFR2 mutations in endometrial carcinoma
- (2008) A. Dutt et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More